Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7261878 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL8099228 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL921170 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL5346543 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL8091263 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL17260635 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL8107486 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL8099646 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| SCHEMBL8099155 | 0.98 | TAAR1 (0.76) | TAAR1TSHRMAOBADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL1222581 | 0.96 | TAAR1 (0.73) | TAAR1TSHRMAOBADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-20140193837-A1 | LUMINESCENT NANOPARTICLE COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-07-10 | — | — | US | claimed |
| WO-2012174287-A1 | LUMINESCENT NANOPARTICLE COMPOSITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-12-20 | — | — | WO | claimed |
| US-5614614-A | ANTIBIOTICS, CHEMICAL INTERMEDIATES | ROUSSEL UCLAF (FR) | 1997-03-25 | — | — | US | claimed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | claimed |
| CN-1090581-A | The preparation method of the novel derivative of erythromycin and they and as the application of medicine | ROUSSEL UCLAF (FR) | 1994-08-10 | — | — | CN | claimed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | claimed |
| US-11072687-B2 | pH sensitive quantum dots for use as cure indicators | THE BOEING COMPANY (US) | 2021-07-27 | — | — | US | disclosed |
| US-10953110-B2 | Dual emissive metal nanoparticles as ratiometric pH indicators | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-23 | — | — | US | disclosed |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | S&T GLOBAL INC. (US) | 2020-05-12 | — | — | US | disclosed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| CN-106687450-B | A kind of indoles amine -2,3- dioxygenase inhibitor and preparation method thereof | 中国科学院上海有机化学研究所 | 2019-08-16 | — | — | CN | disclosed |
| US-20190153165-A1 | pH SENSITIVE QUANTUM DOTS FOR USE AS CURE INDICATORS | THE BOEING COMPANY (US) | 2019-05-23 | — | — | US | disclosed |
| US-5527780-A | BACTERICIDES | ROUSSEL UCLAF (FR) | 1996-06-18 | — | — | US | disclosed |
| EP-0596802-B1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1996-03-20 | — | — | EP | disclosed |
| WO-1995015978-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| CN-1090581-A | The preparation method of the novel derivative of erythromycin and they and as the application of medicine | ROUSSEL UCLAF (FR) | 1994-08-10 | — | — | CN | disclosed |
| EP-0596802-A1 | Erythromycin derivatives, their process of preparation and their application as medicaments | ROUSSEL UCLAF (FR) | 1994-05-11 | — | — | EP | disclosed |
| CN-1057654-A | Bisphosphonic acid derivatives and preparation thereof and application | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1992-01-08 | — | — | CN | disclosed |
| US-4242474-A | A POLYHYDROXY ACRYLIC ESTER REACTED WITH AN ISOCYANATE TERMINATED POLYOXYALKYLENE GLYCOL; BIOPOLYMERS | TERUMO CORPORATION (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953110-B2 | Dual emissive metal nanoparticles as ratiometric pH indicators | CD63, MYADM, CA2 | TAAR1 2185/4885TSHR 1753/4885MAOB 2990/4885 |
| US-10647747-B2 | Cyclosporin derivatives and uses thereof | FKBP5, FKBP1B, MALT1 | TAAR1 3892/4885TSHR 4095/4885MAOB 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.